Lucanthone

硫坎酮

Report date: 2024/02/06 16:32:18
NME

Base Information

Drug NameLucanthone
Drug Alias NameTixantone硫蒽酮lucantonalucanthonum
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTopoisomerase II inhibitors
TargetsTopoisomerase II
Therapy Area/IndicationsBrain metastasesCarcinoma, Non-Small-Cell LungGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIndia
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAlbert Einstein College Of Medicine Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWake Forest University Health SciencesSpectrum Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsBrain metastasesCarcinoma, Non-Small-Cell LungGlioblastoma

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG